Nasopharynx cancer: low serum albumin predicts poor outcomes in meta-analysis

  • Yang H & al.
  • Clin Otolaryngol
  • 1 Oct 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low pretreatment serum albumin predicts poorer outcomes and can be used for risk stratification in nasopharyngeal carcinoma (NPC).

Why this matters

  • Serum albumin is regularly used as a nutritional index in clinical practice.
  • Pretreatment levels have been linked to prognosis in hepatocellular carcinoma, colorectal cancer, and lung cancer.
  • Its value in NPC is controversial due to a paucity of data.

Key results

  • Low pretreatment serum albumin (cutoffs used varied between 35 and 47 g/L) predicted shorter OS (HR, 1.32; P<.001 and distant metastasis-free survival hr>
  • In subgroup analysis, low albumin predicted poorer OS and DMFS in patients with nonmetastatic NPC (HR, 1.40; P<.001 and hr respectively but not in patients with metastatic npc>

Study design

  • Meta-analysis of 10 retrospective studies involving 7339 patients with NPC.
  • Funding: Science and Technology Fund of the Tianjin Health Bureau.

Limitations

  • Heterogeneity between included studies.
  • Only retrospective studies included.